CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
Authors
Lana M Chahine
Christopher S Coffey
+21 more
Christian Czech
Juergen Dukart
Sebastian Dziadek
Tatiana Foroud
Douglas Galasko
Thomas Gerken
Samantha J Hutten
Thomas Kremer
Kenneth Marek
Brit Mollenhauer
Gennaro Pagano
Kathleen L Poston
John Seibyl
Juliane Siebourg-Polster
Tanya Simuni
Andreas Staempfli
Caroline M Tanner
Kirsten I Taylor
Arthur W Toga
Claudia Trenkwalder
Daniel Weintraub
Publication date
1 August 2021
Publisher
eScholarship, University of California
Abstract
BackgroundCerebrospinal fluid (CSF) levels of monoamine metabolites may represent biomarkers of Parkinson's disease (PD).ObjectiveThe aim of this study was quantification of multiple metabolites in CSF from PD versus healthy control subjects (HCs), including longitudinal analysis.MethodsAbsolute levels of multiple monoamine metabolites in CSF were quantified by liquid chromatography coupled with tandem mass spectrometry from 161 individuals with early PD and 115 HCs from the Parkinson's Progression Marker Initiative and de novo PD (DeNoPA) studies.ResultsBaseline levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were lower in individuals with PD compared with HCs. HVA levels correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale total scores (P < 0.01). Both HVA/dopamine and DOPAC/dopamine levels correlated with caudate nucleus and raw DOPAC with putamen dopamine transporter single-photon emission computed tomography uptake ratios (P < 0.01). No metabolite changed over 2 years in drug-naive individuals, but some changed on starting levodopa treatment.ConclusionsHVA and DOPAC CSF levels mirrored nigrostriatal pathway damage, confirming the central role of dopaminergic degeneration in early PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Similar works
Full text
Available Versions
Sustaining member
eScholarship - University of California
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:escholarship.org:ark:/1303...
Last time updated on 25/12/2021